PreMD faces AMEX delisting
This article was originally published in The Gray Sheet
Executive Summary
Three days after firm announces FDA upheld a January 2008 decision that its PreVu skin cholesterol test is not substantially equivalent to standard-of-care blood cholesterol tests, PreMD says the American Stock Exchange plans to suspend trading in PreMD stock effective Aug. 28 and begin delisting proceedings. PreMD received an earlier notice in May of AMEX's intention to delist the company, but ultimately lost an appeal this month
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.